Therapeutic antibodies are one of the fastest growing classes of drugs with the promise of better specificity and safety. Successful antibody discovery campaigns take advantage of technologies that allow for rapid identification and characterization of candidate molecules with superior target reactivity and optimized functionality.
The Intellicyt® iQue Screener PLUS platform saves you time, resources and cost across the biologics discovery workflow.
Click below to see how the Intellicyt iQue Screener PLUS streamlines the three biologics discovery workflow steps antibody screening, functional profiling and bioprocessing.
Get fast and timely access to antibody specificity and species cross reactivity during primary screening with multiplexed cell- and bead-based antibody binding assays.
Easily go from high content functional assays to actionable information that helps you select candidates with desirable biological activity.
Select antibody clones upstream of cell line development by simultaneously detecting IgG titer, cell health and viability.
– Andrea Gorlani, PhD, Scientist ModiQuest Research
The iQue Screener PLUS utilizes a unique and rapid, air-gap-delimited sampling technology paired to a no-adjustment, flow-based detection engine and powerful, easy-to-use ForeCyt® Software for assay management and analysis.
Unlike ELISAs, which can only report on binding to single antigens and require large amounts of target protein to coat entire wells, the iQue Screener PLUS is able to simultaneously acquire data on multiple biological readouts and with much less protein. Using differential fluorescent labeling, multiple cell types and a range of cellular parameters can be assessed all in the same well, quickly generating a rich, highly-informative data set. And because multiple target proteins can be presented on beads or on the cell surface, precious reagents are conserved, reducing costs.
Because the iQue Screener PLUS supports cell-based assays, target proteins can be presented on the cell surface instead of coated on the wells of a plate. By placing the target in its native conformation, results are more likely to be biologically relevant and better indicators of what will happen in vivo.
By sampling only microliters from each well and delivering an air-gap-delimited flow of samples to the detectors, the iQue Screener PLUS converts the traditional low throughput, time-consuming flow cytometry approach into a high throughput process capable of rapidly driving the antibody screening process forward. The end result is a data-rich snapshot of the molecular events occurring in each well that can take less than five minutes for a 96-well plate and under 20 minutes for a 384-well plate.